NASDAQ:TOCATocagen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $20.44 +1.52 (+8.03 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$18.60Now: $20.44▼$20.6350-Day Range$1.26MA: $13.06▼$21.7152-Week Range$0.42Now: $20.44▼$6.77Volume37,064 shsAverage Volume1.47 million shsMarket Capitalization$488.90 millionP/E RatioN/ADividend YieldN/ABeta0.01 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingTocagen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.77, Tocagen has a potential downside of 91.3% from its current price of $20.44.Amount of Analyst CoverageTocagen has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesTocagen has received 243 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTocagen has received 250 “underperform” votes. (Add your “underperform” vote.)Community SentimentTocagen has received 50.71% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote “Outperform” if you believe TOCA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTocagen does not currently pay a dividend.Dividend GrowthTocagen does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tocagen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.90% of the stock of Tocagen is held by insiders.Percentage Held by InstitutionsOnly 21.42% of the stock of Tocagen is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tocagen are expected to grow in the coming year, from ($2.65) to ($2.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tocagen is -8.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tocagen is -8.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTocagen has a P/B Ratio of 45.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.83 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TOCA Previous Symbol CUSIPN/A CIK1419041 Webwww.tocagen.com Phone858-412-8400Debt Debt-to-Equity Ratio1.88 Current Ratio1.15 Quick Ratio1.15Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$40,000.00 Price / Sales12,222.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book45.42Profitability EPS (Most Recent Fiscal Year)($2.69) Net Income$-63,520,000.00 Net Margins-176,433.34% Return on Equity-327.74% Return on Assets-111.87%Miscellaneous Employees77 Outstanding Shares23,919,000Market Cap$488.90 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable $20.44 +1.52 (+8.03 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TOCA News and Ratings via Email Sign-up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. Tocagen (NASDAQ:TOCA) Frequently Asked Questions How has Tocagen's stock been impacted by COVID-19 (Coronavirus)? Tocagen's stock was trading at $1.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TOCA shares have increased by 1,218.7% and is now trading at $20.44. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Tocagen? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tocagen. When is Tocagen's next earnings date? Tocagen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tocagen. How were Tocagen's earnings last quarter? Tocagen Inc (NASDAQ:TOCA) announced its quarterly earnings data on Thursday, April, 23rd. The company reported ($0.43) EPS for the quarter, beating the Zacks' consensus estimate of ($0.44) by $0.01. Tocagen had a negative net margin of 176,433.34% and a negative return on equity of 327.74%. View Tocagen's earnings history. What price target have analysts set for TOCA? 7 brokerages have issued 1 year price targets for Tocagen's stock. Their forecasts range from $1.00 to $3.32. On average, they anticipate Tocagen's share price to reach $1.77 in the next twelve months. This suggests that the stock has a possible downside of 91.3%. View analysts' price targets for Tocagen. Has Tocagen been receiving favorable news coverage? News articles about TOCA stock have been trending very negative on Sunday, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tocagen earned a media sentiment score of -3.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Tocagen. Who are some of Tocagen's key competitors? Some companies that are related to Tocagen include Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Uniqure (QURE), Xencor (XNCR), I-Mab (IMAB), Ironwood Pharmaceuticals (IRWD), Madrigal Pharmaceuticals (MDGL), Corcept Therapeutics (CORT), Intercept Pharmaceuticals (ICPT), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX), Y-mAbs Therapeutics (YMAB), Dicerna Pharmaceuticals (DRNA), INDIVIOR PLC/S (INVVY) and Revance Therapeutics (RVNC). View all competitors. What other stocks do shareholders of Tocagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), Amarin (AMRN), VBI Vaccines (VBIV), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX) and Catalyst Pharmaceuticals (CPRX). Who are Tocagen's key executives? Tocagen's management team includes the following people: Mr. Martin J. Duvall, CEO & Director (Age 57)Mr. Thomas E. Darcy, Co-Founder & Director (Age 68)Dr. Douglas J. Jolly, Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 71)Mr. Mark G. Foletta C.P.A., CPA, Exec. VP & CFO (Age 58)Dr. Harry E. Gruber, Founder, Adviser & Director (Age 66) When did Tocagen IPO? (TOCA) raised $80 million in an initial public offering on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO. What is Tocagen's stock symbol? Tocagen trades on the NASDAQ under the ticker symbol "TOCA." How do I buy shares of Tocagen? Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Tocagen's stock price today? One share of TOCA stock can currently be purchased for approximately $20.44. How big of a company is Tocagen? Tocagen has a market capitalization of $488.90 million and generates $40,000.00 in revenue each year. The company earns $-63,520,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Tocagen employs 77 workers across the globe. What is Tocagen's official website? The official website for Tocagen is www.tocagen.com. How can I contact Tocagen? Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected] This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
